Preview

User

Not a user? Register with this site Forgot your password?

Systemic Hypertension

Advanced search

Role of aldosterone dysregulation in uncontrolled blood pressure and new therapeutic strategies in resistant arterial hypertension. Expert council resolution

https://doi.org/10.38109/2075-082X-2026-1-5-8

Abstract

At the end of April 2025 an expert council meeting was held, devoted to the discussion of the uncontrolled blood pressure, role of aldosterone dysregulation in pathogenesis of uncontrolled and resistant hypertension, and new therapeutic options targeting aldosterone- aldosterone synthase inhibitors. 

About the Authors

Irina E. Chazova
E.I. Chazov National Medical Research Center of Cardiology
Russian Federation

Irina E. Chazova, Dr. of Sci. (Med.), Professor, Acad. of RAS, Chief of the Hypertension Department, A.L. Myasnikov Research Institute of Cardiology,

15a, Academician Chazov St., Moscow, 121552.


Zhanna D. Kobalava
Peoples’ Friendship University of Russia
Russian Federation

Zhanna D. Kobalava, Dr. of Sci. (Med.), Professor, Corresponding Member of RAS, Head of the Department of Internal Diseases with Cardiology and functional Diagnostics Course named after Academician V. S. Moiseev,

6, Miklukho-Maklaya St., Moscow, 117198.


Valery I. Podzolkov
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Valery I. Podzolkov, Dr. of Sci. (Med.), professor, Head of Department of Faculty Therapy No 2, N.V. Sklifosovsky Institute of Clinical Medicine,

8/2, Trubetskaya St., Moscow, 119048.


Anna E. Bragina
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Anna E. Bragina, Dr. of Sci. (Med.), Professor, Professor of the Department of Faculty Therapy No 2, N.V. Sklifosovsky Institute of Clinical Medicine, 

8/2, Trubetskaya St., Moscow, 119048.


Oxana A. Kislyak
Pirogov Russian Federation National Research Medical University
Russian Federation

Oxana A. Kislyak, Dr. of Sci. (Med.), Professor, Professor of the Department of Faculty Therapy, Institute of Clinical Medicine, 

1, Ostrovityanova St., Moscow, 117997.


Nikolay M. Danilov
E.I. Chazov National Medical Research Center of Cardiology
Russian Federation

Nikolay M. Danilov, Dr. of Sci. (Med.), Leading Research of Hypertension Department, A.L. Myasnikov Scientific Research Institute of Clinical Cardiology, 

15a, Academician Chazov St., Moscow, 121552.


Olga A. Sivakova
E.I. Chazov National Medical Research Center of Cardiology
Russian Federation

Olga A. Sivakova, Cand. of Sci. (Med.), Head of the 5th Cardiology Department, A.L. Myasnikov Scientific Research Institute of Clinical Cardiology, 

15a, Academician Chazov St., Moscow, 121552.


Nataliya V. Blinova
E.I. Chazov National Medical Research Center of Cardiology
Russian Federation

Nataliya V. Blinova, Cand. of Sci. (Med.), Senior Researcher, Department of Hypertension, A.L. Myasnikov Institute of Clinical Cardiology, 

15a, Academician Chazov St., Moscow, 121552.


References

1. Global report on hypertension 2025: high stakes – turning evidence into action. Geneva: World Health Organization; 2025. Licence: CC BY-NC-SA 3.0 IGO.

2. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021 Sep 11;398(10304):957-980. https://doi.org/10.1016/s0140-6736(21)01330-1

3. Aksenova A.V., Oshchepkova E.V., Gorbunova E.V., Makarov S.A., Aksenov N.N., Musaeva N.Z., Chazova I.E. Controlled and uncontrolled arterial hypertension: features of mono- and combined antihypertensive therapy (according to the national registry of arterial hypertension, 2019-2022). Systemic Hypertension. 2024;21(2):19-26. (In Russ.) https://doi.org/10.38109/2075-082X-2024-2-17-24

4. Aksenova AV, Sivakova OA, Blinova NV, Danilov NM, Elfimova EM, Kisliak OA, Litvin AYu, Oshchepkova EV, Fomin VV, Chikhladze NM, Shelkova GV, Chazova IE. Russian Medical Society for Arterial Hypertension expert consensus. Resistant hypertension: detection and management. Terapevticheskii Arkhiv (Ter. Arkh). 2021;93(9):1018-1029. https://doi.org/10.26442/00403660.2021.09.201007

5. Ebinger J.E., Kauko A., FinnGen, Bello N.A., Cheng S., Niiranen T. Apparent treatment-resistant hypertension associated lifetime cardiovascular risk in a longitudinal national registry. European Journal of Preventive Cardiology. 2023;30(10):960-968. https://doi.org/10.1093/eurjpc/zwad066

6. Chazova I.E., Chikhladze N.M., Blinova N.V., Aksenova A.V., Alekseeva T.A., Ambatiello L.G., Balanova Yu.A., Bragina A.E., Danilov N.M., Drapkina O.M., Drozdova L.Yu., Ezhov M.V., Elfimova E.M., Zhernakova Yu.V., Zhirov I.V., Kislyak O.A., Litvin A.Yu., Nebieridze D.V., Ostroumova O.D., Podzolkov V.I., Sergienko I.V., Sivakova O.A., Starodubova A.V., Stryuk R.I., Tereshchenko S.N., Trushina O.Yu., Shchelkova G.V. Clinical guidelines of the Russian Medical Society on arterial Hypertension (RSH) and the Eurasian association of Cardiologists (EaC) for the diagnosis and treatment of arterial hypertension (2024). Systemic Hypertension. 2024;21(4):5-110. (In Russ.) https://doi.org/10.38109/2075-082X-2024-4-5-109

7. Tian Z., Barbosa C.V., Lang H., Bauersachs J., Melk A., Schmidt B.M.W. Efficacy of pharmacological and interventional treatment for resistant hypertension: a network meta-analysis. Cardiovasc Res. 2024 Feb 27;120(1):108-119. https://doi.org/10.1093/cvr/cvad165

8. Hargovan M, Ferro A, Aldosterone synthase inhibitors in hypertension: current status and future possibilities. JRSM Cardiovasc Dis. 2014;3:1-9. https://doi.org/10.1177/2048004014522440

9. Leopold JA, Ingelfinger JR. Aldosterone and treatment-resistant hypertension. N Engl J Med. 2023;388(5):464-467. https://doi.org/10.1056/NEJMe2213559

10. Verhovez A, Williams TA, Monticone S, et al. Genomic and non-genomic effects of aldosterone. Curr Signal Transduct Ther. 2012;7(2):132-141. http://doi.org/10.2174/157436212800376708

11. Brown JM, Siddiqui M, Calhoun DA, et al. The unrecognized prevalence of primary aldosteronism: a crosssectional study. Ann Intern Med. 2020;173(1):10-20. https://doi.org/10.7326/M20-0065

12. Yuan YE, Haas AV, Rosner B, et al. Elevated blood pressure and aldosterone dysregulation in young black women versus white women on controlled sodium diets. J Clin Endocrinol Metab. 2024;109(2):e773-e779. https://doi.org/10.1210/clinem/dgad512

13. Papadopoulou-Marketou N, Vaidya A, Dluhy R, et al. Hyperaldosteronism. In: Feingold KR, Anawalt B, Blackman MR, et al, eds. Endotext [Internet]. MDText.com, Inc.; Aug 6, 2020. https://www.ncbi.nlm.nih.gov/books/NBK279065/

14. Inoue K, Goldwater D, Allison M, et al. Serum aldosterone concentration, blood pressure, and coronary artery calcium: the multi-ethnic study of atherosclerosis [article and online supplement]. Hypertension. 2020;76(1):113-120. https://doi.org/10.1161/hypertensionaha.120.15006

15. Crompton M, Skinner LJ, Satchell SC, et al. Aldosterone: essential for life but damaging to the vascular endothelium. Biomolecules. 2023;13(6):1004. https://doi.org/10.3390/biom13061004

16. Bogman K., Schwab D., Delporte M-L. et al. Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2). Hypertension. 2017;69(1):189-196. https://doi.org/10.1161/HYPERTENSIONAHA.116.07716

17. Freeman M.W., Halvorsen Y-D., Marshall W. et al. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. N Engl J Med. 2023;388(5):395-405. https://doi.org/10.1056/NEJMoa2213169

18. Flack J.M., Azizi M., Brown J.M. et al. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. N Engl J Med 2025;393:1363-1374. https://doi.org/10.1056/nejmoa2507109

19. A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension (Bax24) https://clinicaltrials.gov/study/NCT06168409?term=%20NCT06168409%20&rank=1


Review

For citations:

Chazova I.E., Kobalava Zh.D., Podzolkov V.I., Bragina A.E., Kislyak O.A., Danilov N.M., Sivakova O.A., Blinova N.V. Role of aldosterone dysregulation in uncontrolled blood pressure and new therapeutic strategies in resistant arterial hypertension. Expert council resolution. Systemic Hypertension. 2026;23(1):5-8. (In Russ.) https://doi.org/10.38109/2075-082X-2026-1-5-8

Views: 390

JATS XML


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2075-082X (Print)
ISSN 2542-2189 (Online)

OOO InterMedservice
Address: 121069, Russia, Moscow, Stolovy Lane, 6
Tel.: +7 (985) 763-98-00
e-mail: og@intermed.services

 

The media outlet is registered with the Federal Service for Supervision of Communications, Information Technology, and Mass Media (Roskomnadzor). Registration number and date of the decision on media registration: series EL No. FS 77 - 83918 dated 12.09.2022.

 

16+

Processing of personal data
supported by NEICON (Elpub lab)